NCT05685394View on ClinicalTrials.gov

DApagliflozin Cardiovascular Effects on Patients at End-stage REnal Disease

PHASE4RecruitingINTERVENTIONAL

Enrollment

80

Participants

Timeline

Start Date

January 24, 2023

Primary Completion Date

November 1, 2024

Study Completion Date

December 1, 2024

Conditions

End-stage Kidney Disease

Interventions

DRUG

Dapagliflozin

Dapagliflozin 10mg P.O. daily

Trial Locations (1)

13083610

RECRUITING

Centro de Pesquisas Clínicas, Campinas

All Listed Sponsors

lead

University of Campinas, Brazil

OTHER